A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma.

[1]  P. Kantoff,et al.  Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[3]  H. Moch,et al.  First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[5]  K. Flaherty,et al.  Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Olencki,et al.  A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma , 2011, Journal of immunotherapy.

[7]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[8]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[9]  C. Antonescu,et al.  KIT as a therapeutic target in metastatic melanoma. , 2011, JAMA.

[10]  Yang Zhang,et al.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  C. Cui,et al.  Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases , 2011, BMC Cancer.

[12]  K. Flaherty,et al.  Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma , 2011, Clinical Cancer Research.

[13]  Paul S Mischel,et al.  Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[15]  J. Lundin,et al.  A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-α2a as first line treatment in metastatic melanoma , 2010, Melanoma research.

[16]  E. Small,et al.  Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Testori,et al.  Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Ott,et al.  Novel therapeutics for melanoma , 2009, Expert review of anticancer therapy.

[19]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[20]  G. Linette,et al.  Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[22]  J. Kirkwood,et al.  Endostatin plus interferon-&agr;2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents , 2007, Melanoma research.

[23]  Helen X. Chen,et al.  A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma , 2007, Annals of Surgical Oncology.

[24]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[25]  Qinghua Zhou,et al.  [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]. , 2005, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[26]  R. Kalluri,et al.  Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  L. Hlatky,et al.  Endostatin: the logic of antiangiogenic therapy. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[28]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[29]  M. Weichenthal,et al.  Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  F. Vidal-Vanaclocha,et al.  Inhibition of Cytokine-Induced Microvascular Arrest of Tumor Cells by Recombinant Endostatin Prevents Experimental Hepatic Melanoma Metastasis , 2004, Cancer Research.

[31]  Andreas Friedl,et al.  Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Ellis,et al.  Phase I study of recombinant human endostatin in patients with advanced solid tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Donald W Kufe,et al.  Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  V. Sukhatme,et al.  Endostatin is a potential inhibitor of Wnt signaling , 2002, The Journal of cell biology.

[35]  R. Mcgarry,et al.  Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials , 2001, Melanoma research.

[36]  S. Ugurel,et al.  Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  K. W. Kim,et al.  Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. , 2000, Cancer research.

[38]  V. Sukhatme,et al.  Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. , 2000, Cancer research.

[39]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[40]  T. Pawlik,et al.  Mouse endostatin inhibits the formation of lung and liver metastases. , 1999, Cancer research.

[41]  J. Zeuthen,et al.  Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. , 1999, Melanoma research.

[42]  M. Atkins,et al.  Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[44]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[45]  G. Linette,et al.  BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  S. Yuan,et al.  Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys , 2005, Acta Pharmacologica Sinica.

[47]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.